🇺🇸 FDA
Pipeline program

Lubiprostone

07-096

Approved small_molecule completed

Quick answer

Lubiprostone for Inflammatory Bowel Disease is a Approved program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Inflammatory Bowel Disease
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials